Pink Pony Peptides FDA Warning Letter: Letter 721088

Updated August 23, 2026

Lovega LLC, doing business as Pink Pony Peptides of Wellington, Florida, received FDA warning letter 721088, dated March 31, 2026 and posted to the agency's public index on April 7, 2026. It is one of seven letters FDA issued to research-peptide sellers on that date.

Letter record

Reading the number

FDA's address for the letter carries both identifiers: 721088 is the letter number, and the suffix 03312026 is the letter date. The full text sits on the agency's site at that address, linked under Sources. This page does not paraphrase the letter beyond the batch findings below; the primary document is one click away.

The March 31 batch

Letter 721088 did not arrive alone. FDA signed warning letters to seven research-peptide sellers on March 31, 2026, and posted all seven on April 7. Recipients were located in Florida, Colorado, Arizona, California, Michigan, and Illinois — Pink Pony Peptides is one of two Florida recipients. No other single date in this index's record carries as many letters to sellers in this category. The complete batch, with all seven letter numbers, is tabulated at the April 2026 batch record.

Findings documented across the batch

Two findings recur through the seven letters. The first concerns language: product pages carrying therapeutic-effect descriptions of compounds labeled for research use. The second concerns the checkout itself: administration supplies offered in the same cart as the compounds. The second finding needs no marketing copy at all — in the letters, what a cart pairs together stands as evidence of how the products were meant to be used.

The agency's disclaimer position

The batch answers the research-use-only disclaimer question directly. FDA's stated position, quoted from the letters: "evidence obtained from your website establishes that your products are intended to be drugs for human use."

Coded product names

Coverage of the batch also documents coded listing names — "GLP-1 SM" and "GLP-3 RT" are the recorded examples — which the agency, per the letters, read as circumvention rather than caution. This index holds that finding at batch level only; the two examples are not attributed here to Pink Pony Peptides or to any other single recipient.

Where this record stops

This index has not captured a response deadline for the March 2026 batch, and it records no response from Lovega LLC. Nothing on this page describes what the company did after March 31, 2026, in either direction. Pink Pony Peptides also carries an entry in the vendor index, alongside every other recipient in the verified record.

Sources

1. FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
2. FDA Warning Letters index. fda.gov
3. Partnership for Safe Medicines, PDF summary of the seven letters (posted April 7, 2026). safemedicines.org

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.